CLAIMS

1. A compound represented by the following structural formula:



Formula **I**

a tautomer thereof, a deuterated derivative of that compound or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein:

X^1 is selected from S and -C**R^{2a}** and **X^2** is selected from S and -C**R^{2b}**, wherein:

one of **X^1** and **X^2** is S;

when **X^1** is S, then **X^2** is -C**R^{2b}**; and

when **X^2** is S, then **X^1** is -C**R^{2a}**;

R^1 is selected from hydrogen, halogen, cyano, -OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_3-C_6 cycloalkyl, and phenyl, wherein:

the C_1-C_6 alkyl of **R^1** is optionally substituted with 1 to 3 groups independently selected from halogen, cyano, -OH, -NH_2, -NH(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)$_2$, and C_1-C_4 alkoxy;

the C_1-C_6 alkoxy of **R^1** is optionally substituted with 1 to 3 groups independently selected from halogen;

the C_3-C_6 cycloalkyl of **R^1** is optionally substituted with 1 to 3 groups independently selected from halogen, cyano, -OH, -NH_2, -NH(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)$_2$, C_1-C_4 alkyl, C_1-C_4 alkoxy, -C(=O)NH_2, -C(=O)NH(C_1-C_4 alkyl), and -C(=O)N(C_1-C_4 alkyl)$_2$; and

the phenyl of **R^1** is optionally substituted with 1 to 3 groups independently selected from halogen, cyano, -OH, -NH_2, -NH(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)$_2$, C_1-

C_4 alkyl, C_1-C_4 alkoxy, -C(=O)NH_2, -C(=O)NH(C_1-C_4 alkyl), and -C(=O)N(C_1-C_4 alkyl)$_2$;

R^{2a} is selected from hydrogen, halogen, cyano, -OH, =O, and C_1-C_6 alkyl, wherein:

the C_1-C_6 alkyl of **R^{2a}** is optionally substituted with 1 to 3 groups independently selected from halogen, cyano, -OH, and C_1-C_4 alkoxy;

R^{2b} is selected from hydrogen, halogen, cyano, -OH, =O, and C_1-C_6 alkyl;

R^{3a} is selected from halogen, cyano, -OH, C_1-C_6 alkyl, and =O; wherein:

the C_1-C_6 alkyl of **R^{3a}** is optionally substituted with 1 to 3 groups independently selected from halogen, cyano, and -OH;

R^{3b} is selected from C_1-C_2 alkyl and =O; wherein:

the C_1-C_2 alkyl of **R^{3b}** is optionally substituted with 1 to 3 groups independently selected from halogen, cyano, and -OH;

------, for each occurrence, is a single bond when **R^{3a}** is selected from halogen, cyano, -OH, C_1-C_6 alkyl or when **R^{3b}** is selected from C_1-C_2 alkyl; or alternatively ------, for each occurrence, is a double bond when **R^{3a}** is =O or when **R^{3b}** is =O;

R^4 is selected from C_1-C_6 alkyl, -C(=O)O(C_1-C_4 alkyl), C_2-C_6 alkynyl, and



, wherein:

the C_1-C_6 alkyl of **R^4** is optionally substituted with 1 to 3 groups independently selected from halogen, cyano, -OH, -NH_2, -NH(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)$_2$, C_1-C_4 alkoxy, -C(=O)NH_2, -C(=O)NH(C_1-C_4 alkyl), -C(=O)N(C_1-C_4 alkyl)$_2$, C_3-C_6 cycloalkyl, 5 to 10-membered heterocyclyl, phenyl, and 5 to 10-membered heteroaryl;

Ring A is selected from C_3-C_{12} carbocyclyl, 3 to 12-membered heterocyclyl, C_6 and C_{10} aryl, and 5 to 10-membered heteroaryl, wherein **Ring A** is optionally substituted with 1, 2, 3, 4, or 5 **R^a** groups; wherein:

R^a, for each occurrence, is independently selected from halogen, cyano, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_1-C_6 alkoxy, C_1-C_6 haloalkyl, C_1-C_6 haloalkenyl, C_1-C_6 haloalkoxy, -C(=O)N**R^h****R^i**, -N**R^h****R^i**, -N**R^h**C(=O)**R^k**, -N**R^h**C(=O)O**R^k**, -N**R^h**C(=O)N**R^i****R^j**, -N**R^h**S(=O)$_p$**R^k**, -O**R^k**, -OC(=O)**R^k**,

-OC(=O)O$\mathbf{R^k}$, -OC(=O)N$\mathbf{R^hR^i}$, -[O(CH_2)$_\mathbf{q}$]$_r$O(C_1-C_6 alkyl), -S(=O)$_\mathbf{p}$$\mathbf{R^k}$, -S(=O)$_\mathbf{p}N\mathbf{R^hR^i}$, -C(=O)O$\mathbf{R^k}$, C_3-C_{12} carbocyclyl, 3- to 12-membered heterocyclyl, C_6 and C_{10} aryl, and 5- to 10-membered heteroaryl; wherein:

the C_1-C_6 alkyl, C_1-C_6 alkoxy, and the C_2-C_6 alkenyl of $\mathbf{R^a}$ are each optionally substituted with 1 to 3 groups independently selected from C_6 to C_{10} aryl (optionally substituted with 1 to 3 $\mathbf{R^m}$ groups), 5- to 10-membered heterocyclyl (optionally substituted with 1 to 3 $\mathbf{R^m}$ groups), 5- to 10-membered heteroaryl (optionally substituted with 1 to 3 $\mathbf{R^m}$ groups), cyano, -C(=O)$\mathbf{R^k}$, -C(=O)O$\mathbf{R^k}$, -C(=O)N$\mathbf{R^hR^i}$, -N$\mathbf{R^hR^i}$, -N$\mathbf{R^h}$C(=O)$\mathbf{R^k}$, -N$\mathbf{R^h}$C(=O)O$\mathbf{R^k}$, -N$\mathbf{R^h}$C(=O)N$\mathbf{R^iR^j}$, -N$\mathbf{R^h}$S(=O)$_\mathbf{p}$$\mathbf{R^k}$, -O$\mathbf{R^k}$, -OC(=O)$\mathbf{R^k}$, -OC(=O)O$\mathbf{R^k}$, -OC(=O)N$\mathbf{R^hR^i}$, -S(=O)$_\mathbf{p}$$\mathbf{R^k}$, -S(=O)$_\mathbf{p}N\mathbf{R^hR^i}$, and C_3-C_6 carbocyclyl (optionally substituted with 1 to 3 $\mathbf{R^m}$ groups);

the C_3-C_{12} carbocyclyl, the 3 to 12-membered heterocyclyl, the C_6 and C_{10} aryl, and the 5 to 10-membered heteroaryl of $\mathbf{R^a}$ are each optionally substituted with 1 to 3 groups independently selected from halogen, cyano, C_1-C_4 alkyl, -N$\mathbf{R^hR^i}$, and -O$\mathbf{R^k}$; wherein:

$\mathbf{R^h}$, $\mathbf{R^i}$, and $\mathbf{R^j}$, for each occurrence, are each independently selected from hydrogen, C_1-C_4 alkyl, C_6-C_{10} aryl, and C_3-C_6 cycloalkyl; wherein:

the C_1-C_4 alkyl of any one of $\mathbf{R^h}$, $\mathbf{R^i}$, and $\mathbf{R^j}$ is optionally substituted with 1 to 3 groups independently selected from halogen, cyano, and -OH;

$\mathbf{R^k}$, for each occurrence, are each independently selected from hydrogen, C_1-C_4 alkyl, 5- to 10-membered heterocyclyl, and C_3-C_6 carbocyclyl; wherein:

the C_1-C_4 alkyl of any one of $\mathbf{R^k}$ is optionally substituted with 1 to 3 groups independently selected from halogen, cyano, and -OH;

$\mathbf{R^m}$, for each occurrence, is independently selected from halogen, cyano, oxo, C_1-C_6 alkyl, C_1-C_6 alkoxy, -S(=O)$_\mathbf{p}\mathbf{R^k}$, and -O$\mathbf{R^k}$; wherein:

the C_1-C_6 alkyl of $\mathbf{R^m}$ is optionally substituted with 1 to 3 groups independently selected from halogen, cyano, and -OH;

$\mathbf{R^5}$ is selected from C_1-C_6 alkyl, -C(=O)O(C_1-C_4 alkyl), C_3-C_{12} carbocyclyl, 3- to 12-membered heterocyclyl, C_6 and C_{10} aryl, and 5- to 10-membered heteroaryl; wherein:

the C_1-C_6 alkyl of $\mathbf{R^5}$ is optionally substituted with 1 to 3 groups independently selected from halogen, cyano, -OH, -NH_2, -NH(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)$_2$, C_1-C_4 alkoxy, -C(=O)NH_2, -C(=O)NH(C_1-C_4 alkyl), and -C(=O)N(C_1-C_4 alkyl)$_2$;

the C_3-C_{12} carbocyclyl, the 3 to 12-membered heterocyclyl, the C_6 and C_{10} aryl, and the 5 to 10-membered heteroaryl of $\mathbf{R^5}$ are each optionally substituted with 1 to 3 groups independently selected from halogen, cyano, -OH, -NH_2, -NH(C_1-C_4 alkyl) (optionally substituted with -OH), -N(C_1-C_4 alkyl)$_2$, C_1-C_5 alkyl (optionally substituted with -OH), C_1-C_4 alkoxy, -C(=O)NH_2, -C(=O)NH(C_1-C_4 alkyl), -NHC(=O)(C_1-C_4 alkyl), -C(=O)(C_1-C_4 alkoxy), and -C(=O)N(C_1-C_4 alkyl)$_2$;

k is an integer selected from 0, 1, and 2, wherein:

when $\mathbf{R^{3a}}$ is selected from halogen, cyano, -OH, and C_1-C_6 alkyl, k is 1 or 2; and

when $\mathbf{R^{3a}}$ is =O, k is 1;

m is an integer selected from 0, 1, and 2, wherein:

when $\mathbf{R^{3b}}$ is selected from C_1-C_2 alkyl, m is 1 or 2; and

when $\mathbf{R^{3b}}$ is =O, **m** is 1;

p is an integer selected from 1 and 2; and

q and **r** are each an integer selected from 1, 2, 3, and 4.

2. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to claim 1, wherein the compound is represented by one of the following structural formulae:



Formula **IIa**



Formula **IIb**

a tautomer thereof, a deuterated derivative of that compound or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein:

R^{2a} is selected from hydrogen, halogen, cyano, and C_1-C_4 alkyl; wherein:

the C_1-C_4 alkyl of **R^{2a}** is optionally substituted with 1 to 3 groups independently selected from halogen, -OH, and C_1-C_2 alkoxy;

R^{2b} is selected from hydrogen, halogen, cyano, and C_1-C_4 alkyl; and

k is an integer selected from 0, 1, and 2.

3. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to claim 1 or claim 2, wherein **R^4** is selected from C_1-C_4 alkyl and



; wherein:

the C_1-C_4 alkyl of **R^4** is optionally substituted with 1 to 3 groups independently selected from halogen, cyano, -OH, -NH_2, -NH(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)$_2$, C_1-C_2 alkoxy, C_3-C_6 cycloalkyl, 5 to 6-membered heterocyclyl, phenyl, and 5 to 6-membered heteroaryl.

4. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 4, wherein **R^4** is selected from C_1-C_2 alkyl and



; wherein:

the C_1-C_2 alkyl of **R^4** is optionally substituted with 1 to 3 groups independently selected from halogen, cyano, -OH, and 5 to 6-membered heterocyclyl.

5. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 4, wherein **R^4** is selected from $-CH_3$, $-CH_2OH$, and (tetrahydro-2H-pyran-4-yl)methyl.

6. The compound according to any one of claims 1 to 4, wherein the compound is represented by one of the following structural formulae:



Formula **IIIa**



Formula **IIIb**

a tautomer thereof, a deuterated derivative of that compound or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein:

Ring A, for each occurrence, is selected from C_3-C_6 cycloalkyl, 5- to 10-membered heterocyclyl, phenyl, and 5- to 10-membered heteroaryl; each of which is optionally substituted with 1, 2, 3, 4, or 5 **R^a** groups.

7. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 4 and 6, wherein **Ring A** is selected from cyclopropyl, 5- to 10-membered heterocyclyl, phenyl, and 5- to 9-membered heteroaryl; each of which is optionally substituted with 1, 2, 3, 4, or 5 **R^a** groups.

8. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 4, 6, and 7, wherein **Ring A** is selected from cyclopropyl, 5- to 10-membered heterocyclyl containing 1 to 3 heteroatoms selected from N and O, phenyl, and 5- to 9-membered heteroaryl containing 1 to 3 heteroatoms selected from N and O; each of which is optionally substituted with 1, 2, 3, 4, or 5 **R^a** groups.

9. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 4 and 6 to 8, wherein **Ring A** is selected from cyclopropyl, 5-membered heterocyclyl containing 1 to 3 heteroatoms selected from N and O, 6-membered heterocyclyl containing 1 to 3 heteroatoms selected from N and O, 9-membered heterocyclyl containing 1 to 3 heteroatoms selected from N and O, 10-membered heterocyclyl containing 1 to 3 heteroatoms selected from N and O, phenyl, 5-membered heteroaryl containing 1 to 3 heteroatoms selected from N and O, 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N and O, and 9-membered heteroaryl containing 1 to 3 heteroatoms selected from N and O; each of which is optionally substituted with 1, 2, 3, 4, or 5 **R^a** groups.

10. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 4 and 6 to 9, wherein **Ring A** is selected from



, , , , , , , , , , , , , , , and ; each of which is optionally substituted with 1, 2, 3, 4, or 5 **R**[a] groups.

11. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 4 and 6 to 10, wherein **Ring A** is selected from

, , , , , , , , , , , , , , , , , ,


; each of which is optionally substituted with 1, 2, 3, 4, or 5 **R**^{a} groups.

12. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 4 and 6 to 11, wherein **R^4** is selected from -CH_3 and **Ring A**; wherein **Ring A** is selected from , , , , , , , , , , , and ; each of which is optionally substituted with 1, 2, 3, 4, or 5 **R^a** groups.

13. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 12, wherein **R^5** is selected from C_1-C_4 alkyl, -C(=O)O(C_1-C_2 alkyl), C_3-C_6 cycloalkyl, and 5- to 10-membered heterocyclyl; wherein:

the C_1-C_4 alkyl of **R^5** is optionally substituted with 1 to 3 groups independently selected from halogen, cyano, -OH, and C_1-C_2 alkoxy; and

the C_3-C_6 cycloalkyl and the 5 to 10-membered heterocyclyl of **R^5** are each optionally substituted with 1 to 3 groups independently selected from halogen, cyano, -OH, C_1-C_2 alkyl, and C_1-C_2 alkoxy.

14. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 13, wherein **R^5** is selected from C_1-C_2 alkyl, -C(=O)O(C_1-C_2 alkyl), cyclopropyl, cyclobutyl, and 5- to 6-membered heterocyclyl; wherein:

the C_1-C_2 alkyl of **R^5** is optionally substituted with 1 to 3 groups independently selected from F, Cl, Br, cyano, -OH, and C_1-C_2 alkoxy; and

the cyclopropyl, the cyclobutyl, and the 5- to 6-membered heterocyclyl of **R^5** are each optionally substituted with 1 to 3 groups independently selected from F, Cl, Br, cyano, -OH, C_1-C_2 alkyl, and C_1-C_2 alkoxy.

15. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 14, wherein **R^5** is selected from $-CH_3$, $-CH_2CH_3$, $-CH_2OH$, $-C(=O)OCH_3$, $-CH_2OCH_3$, $-CH(CH_3)_2$, cyclopropyl, difluorocyclopropyl, and tetrahydro-2H-pyranyl.

16. The compound according to any one of claims 1 to 15, wherein the compound is represented by one of the following structural formulae:



Formula **IVa**



Formula **IVb**

a tautomer thereof, a deuterated derivative of that compound or tautomer, or a pharmaceutically acceptable salt of any of the foregoing.

17. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 16, wherein **R^1** is selected from hydrogen, halogen, cyano, -OH, C_1-C_4 alkyl, C_1-C_4 alkoxy, and C_3-C_6 cycloalkyl; wherein:

the C_1-C_4 alkyl of **R^1** is optionally substituted with 1 to 3 groups independently selected from halogen, cyano, -OH, and C_1-C_2 alkoxy;

the C_1-C_4 alkoxy of **R^1** is optionally substituted with 1 to 3 independently selected halogen groups; and

the C_3-C_6 cycloalkyl of **R^1** is optionally substituted with 1 to 3 groups independently selected from halogen, cyano, -OH, and C_1-C_2 alkoxy.

18. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 17, wherein **R^1** is selected from F, Cl, Br, C_1-C_4 alkyl, and C_3-C_6 cycloalkyl; wherein:

the C_1-C_4 alkyl of **R^1** is optionally substituted with 1 to 3 groups independently selected from halogen and -OH; and

the C_3-C_6 cycloalkyl of **R^1** is optionally substituted with 1 to 3 groups independently selected from halogen, and -OH.

19. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 16, wherein **R^1** is selected from Cl, Br, $-CH_3$, $-CF_3$, $-CH_2CH_3$, $-CH(CH_3)_2$, $-CH_2CHF_2$, $-CH_2CH(CH_3)_2$, difluorocyclobutyl, and cyclohexyl.

20. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 19, wherein **R^1** is Cl.

21. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 20, wherein **R^{3a}** is selected from halogen, -OH, and C_1-C_4 alkyl; wherein:

the C_1-C_4 alkyl of **R^{3a}** is optionally substituted with 1 to 3 groups independently selected from halogen and -OH.

22. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 21, wherein **R^{3a}** is selected from F, Cl, Br, -OH, and C_1-C_2 alkyl; wherein:

the C_1-C_2 alkyl of **R^{3a}** is optionally substituted with 1 to 3 groups independently selected from F, Cl, and -OH.

23. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 22, wherein **R^{3a}** is selected from F, -OH, $-CH_3$, $-CHF_2$, and CH_2OH.

24. The compound according to any one of claims 1 to 4 and 6 to 23, wherein the compound is represented by one of the following structural formulae:



Formula **Va**



Formula **Vb**

a tautomer thereof, a deuterated derivative of that compound or tautomer, or a pharmaceutically acceptable salt of any of the foregoing.

25. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 4 and 6 to 24, wherein $\mathbf{R^a}$, for each occurrence, is independently selected from halogen, cyano, C_1-C_6 alkyl, C_1-C_4 alkoxy, C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, -C(=O)N$\mathbf{R^h R^i}$, -N$\mathbf{R^h R^i}$, -N$\mathbf{R^h}$C(=O)$\mathbf{R^k}$, -O$\mathbf{R^k}$, -[O(CH_2)$_\mathbf{q}$]$_r$O(C_1-C_6 alkyl), -S(=O)$_2\mathbf{R^k}$, -S(=O)$_\mathbf{2}$N$\mathbf{R^h R^i}$, C_3-C_6 cycloalkyl, 5- to 10-membered heterocyclyl, phenyl, and 5- to 8-membered heteroaryl; wherein:

the C_1-C_6 alkyl of $\mathbf{R^a}$ is optionally substituted with 1 to 3 groups independently selected from cyano, -C(=O)N$\mathbf{R^h R^i}$, -N$\mathbf{R^h R^i}$, -N$\mathbf{R^h}$C(=O)$\mathbf{R^k}$, -N$\mathbf{R^h}$C(=O)O$\mathbf{R^k}$, -N$\mathbf{R^h}$C(=O)N$\mathbf{R^i R^j}$, -N$\mathbf{R^h}$S(=O)$_\mathbf{p}\mathbf{R^k}$, -O$\mathbf{R^k}$, -S(=O)$_2\mathbf{R^k}$, -S(=O)$_\mathbf{p}$N$\mathbf{R^h R^i}$, and C_3-C_6 cycloalkyl;

the C_3-C_6 cycloalkyl, the 5 to 10-membered heterocyclyl, the phenyl, and the 5- to 8-membered heteroaryl of $\mathbf{R^a}$ are each optionally substituted with 1 to 3 groups independently selected from halogen, C_1-C_2 alkyl, and -O$\mathbf{R^k}$; wherein:

$\mathbf{R^h}$, $\mathbf{R^i}$, and $\mathbf{R^j}$, for each occurrence, are each independently selected from hydrogen, C_1-C_2 alkyl, cyclopropyl, and cyclobutyl; wherein:

the C_1-C_2 alkyl of any one of $\mathbf{R^h}$, $\mathbf{R^i}$, and $\mathbf{R^j}$ is optionally substituted with 1 to 3 groups independently selected from halogen and -OH;

$\mathbf{R^k}$, for each occurrence, are each independently selected from hydrogen and C_1-C_4 alkyl; wherein:

the C_1-C_4 alkyl of $\mathbf{R^k}$ is optionally substituted with 1 to 3 groups independently selected from halogen and -OH; and

q and **r** are each an integer selected from 1, 2, and 3.

26. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 4 and 6 to 25, wherein $\mathbf{R^a}$, for each occurrence, is independently selected from halogen, cyano, C_1-C_6 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, C_1-C_4 haloalkoxy, -C(=O)N$\mathbf{R^h R^i}$, -N$\mathbf{R^h R^i}$, -N$\mathbf{R^h}$C(=O)$\mathbf{R^k}$, -O$\mathbf{R^k}$, -[O(CH_2)$_\mathbf{q}$]$_r$O(C_1-C_4 alkyl), -S(=O)$_2\mathbf{R^k}$, -S(=O)$_\mathbf{2}$N$\mathbf{R^h R^i}$, cyclopropyl, cyclobutyl, 5 to 6-membered heterocyclyl, phenyl, and 5 to 6-membered heteroaryl; wherein:

the C_1-C_6 alkyl of $\mathbf{R^a}$ is optionally substituted with 1 to 3 groups independently selected from cyano, -C(=O)N$\mathbf{R^h R^i}$, -N$\mathbf{R^h R^i}$, -O$\mathbf{R^k}$, cyclopropyl, and cyclobutyl;

the cyclopropyl, the cyclobutyl, the 5 to 6-membered heterocyclyl, the phenyl, and the 5 to 6-membered heteroaryl of $\mathbf{R^a}$ are each optionally substituted with 1 to 3 groups independently selected from halogen, -CH_3, -OH, and -OCH_3;

$\mathbf{R^h}$ and $\mathbf{R^i}$, for each occurrence, are each independently selected from hydrogen, -CH_3, cyclopropyl, and cyclobutyl; wherein:

the -CH_3 of any one of $\mathbf{R^h}$ and $\mathbf{R^i}$ is optionally substituted with 1 to 3 groups independently selected from F, Cl, and -OH;

$\mathbf{R^k}$, for each occurrence, is each independently selected from hydrogen and -CH_3; wherein:

the -CH_3 of $\mathbf{R^k}$ is optionally substituted with 1 to 3 groups independently selected from halogen and -OH.

27. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 4 and 6 to 26, wherein $\mathbf{R^a}$, for each occurrence, is independently selected from F, Cl, Br, cyano, C_1-C_6 alkyl, C_1-C_2 alkoxy, C_1-C_2 haloalkyl, -C(=O)N$\mathbf{R^h R^i}$, -N$\mathbf{R^h R^i}$, -N$\mathbf{R^h}$C(=O)$\mathbf{R^k}$, -O$\mathbf{R^k}$, -[O(CH_2)$_\mathbf{q}$]$_r$O(C_1-C_2 alkyl), -S(=O)$_2\mathbf{R^k}$, -S(=O)$_\mathbf{2}$N$\mathbf{R^h R^i}$, cyclopropyl, cyclobutyl, 5-membered heterocyclyl, phenyl, and 6-membered heteroaryl; wherein:

the C_1-C_6 alkyl of $\mathbf{R^a}$ is optionally substituted with 1 to 3 groups independently selected from cyano, -C(=O)N$\mathbf{R^h R^i}$, -O$\mathbf{R^k}$, and cyclopropyl;

the cyclopropyl, the cyclobutyl, the 5 to 6-membered heterocyclyl, the phenyl, and the 5 to 6-membered heteroaryl of **R^{a}** are each optionally substituted with 1 to 3 groups independently selected from halogen, -CH_3, -OH, and -OCH_3; wherein:

R^{h} and **R^{i}**, for each occurrence, are each independently selected from hydrogen, -CH_3, and cyclopropyl; wherein:

the -CH_3 of any one of **R^{h}** and **R^{i}** is optionally substituted with 1 to 3 groups independently selected from F, Cl, and -OH;

R^{k}, for each occurrence, is each independently selected from hydrogen and -CH_3; and

q and **r** are each an integer selected from 1 and 2.

28. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 4 and 6 to 27, wherein **R^{a}**, for each occurrence, is independently selected from F, cyano, -OH, -CH_3, -CF_3, -$CH(CH_3)_2$, -$(CH_2)_2OH$, -$(CH_2)_2OCH_3$, -$CH_2CH(OH)C_2H_5$, -$CH_2C(CH_3)(CH_2OH)_2$, -OCH_3, -OCH_2CH_3, -$[O(CH_2)_2]_2OCH_3$, -$CH_2C(=O)NHCH_3$, -$(CH_2)_2SO_2CH_3$, -$CH_2C(=O)N(CH_3)_2$, -CH_2(cyclopropyl), -$C(=O)NH_2$, -C(=O)NH(cyclopropyl), -NH_2, -$NHCH_3$, -$N(CH_3)_2$, -$NHC(CH_3)_2CH_2OH$, -$NHC(=O)CH_3$, -SO_2CH_3, -SO_2NH_2, cyclopropyl, 2-methoxyphenyl, N-methylpiperazinyl, tetrahydro-2H-pyranyl, methylpyrazolyl, pyridinyl, and tetrahydrothiophenyl 1,1-dioxide.

29. The compound according to claim 1, wherein the compound is represented by one of the following structural formulae:



Formula **I'**



Formula **IIa'**



Formula **IIb'**



Formula **IIIa'**



Formula **IIIb'**



Formula **IVa'**



Formula **IVb'**



Formula **Va'**



Formula **Vb'**

a tautomer thereof, a deuterated derivative of that compound or tautomer, or a pharmaceutically acceptable salt of any of the foregoing.

30. A compound selected from:



1



2



3



4



5



6



7



8



9



10



11



12



13



14



15



16



17



18


19


20


21


22


23


24


25


26


27


28


29


30


31


32


33


34


35


36



37



38



39



40



41



42



43



44



45



46



47



48



49



50



51



52



53



54


55


56


57


58


59


60


61


62


63


64


65


66


67


68


69


70


71


72


73


74


75


76


77


78


79


80


81


82


83


84


85


86


87


88


89


90



91



92



93



94



95



96



97



98



99



100



101



102



103



104



105



106



107



108



109



110



111



112



113



114



115



116



117



118



119



120



121



122



123



124



125



126



127



128



129



130



131



132



133



134



135



136



137



138



139



140



141



142



143



144


145


146


147


148


149


150


151


152


153


154


155


156


157


158


159


160


161


162



163



164



165



166



167



168



169



170



171



172



173



174



175



176



177



178



179



180



181



182



183



184



185



186



187



188



189



190



191



192



193



194



195



196



197



198



199



200



201



202



203



204



205



206



207



208



209



210



211



212



213



214



215



216



217



218



219



220



221



222



223



224



225



226



227



228



229



230



231



232



233



234



235



236



237



238



239



240



241



242



243



244



245



246



247



248



249



250



251



252


253


254


255


256


257


258


259


260


261


262


263


264


265


266


267


268



269



270



271



272



273



274



275



276



277



278



279



280



281



282



283



284


285


286


287


288


289


290


291


292


293


294


295


296


297


298


299


300



301



302



303



304



305



306



307



308



309



310



311



312



313



314



315



316


317


318


319


320


321


322


323


324


325


326


327


328


329


330


331


332



333



334



335



336



337



338



339



340



341



342



343



344



345



346



347



348



349



350



351



352



353



354



355



356



357



358



359



360



361



362



363



364



365



366



367



368



369



370



371



372



373



374



375



376



377



378



379



380



tautomers thereof, deuterated derivatives of those compounds and tautomers, and pharmaceutically acceptable salts of any of the foregoing.

31. A compound selected from Compound 174:



,

a tautomer of Compound 174, a deuterated derivative of Compound 174 or tautomer thereof, and a pharmaceutically acceptable salt of any of the foregoing.

32. A compound selected from Compound 174:



174 ,

and a pharmaceutically acceptable salt of Compound 174.

33. A compound that is:



174 .

34. A compound selected from Compound 181:



181 ,

a tautomer of Compound 181, a deuterated derivative of Compound 181 or tautomer thereof, and a pharmaceutically acceptable salt of any of the foregoing.

35. A compound selected from Compound 181:



181 ,

and a pharmaceutically acceptable salt of Compound 181.

36. A compound that is:



181

.

37. A pharmaceutical composition comprising the compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 36 and a pharmaceutically acceptable carrier.

38. Use of the compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 36 or the pharmaceutical composition according to claim 37, in the manufacture of a medicament for treating focal segmental glomerulosclerosis and/or non-diabetic kidney disease.

39. Use of the compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 36 or the pharmaceutical composition according to claim 37, in the manufacture of a medicament for treating pancreatic cancer, end-stage kidney disease (ESKD), non-diabetic kidney disease (NDKD), focal segmental glomerulosclerosis (FSGS), HIV-associated nephropathy, arterionephrosclerosis, lupus nephritis, microalbuminuria, chronic kidney disease, and/or proteinuria..

40. Use of the compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 36 or the pharmaceutical composition according to claim 37, in the manufacture of a medicament for treating an APOL1-mediated disease.

41. The use according to claim 40, wherein the APOL1-mediated disease is cancer.

42. The use according to claim 40 or claim 41, wherein the APOL1-mediated disease is pancreatic cancer.

43. The use according to claim 40, wherein the APOL1-mediated disease is an APOL1-mediated kidney disease.

44. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 36 or the pharmaceutical composition according to claim 37, for use in the treatment of focal segmental glomerulosclerosis and/or non-diabetic kidney disease.

45. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 36 or the pharmaceutical composition according to claim 37, for use in the treatment of pancreatic cancer, end-stage kidney disease (ESKD), non-diabetic kidney disease (NDKD), focal segmental glomerulosclerosis (FSGS), HIV-associated nephropathy, arterionephrosclerosis, lupus nephritis, microalbuminuria, chronic kidney disease, and/or proteinuria.

46. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 36 or the pharmaceutical composition according to claim 37, for use in the treatment of an APOL1-mediated disease.